Skip to main content
Top
Published in: Heart and Vessels 5/2017

01-05-2017 | Original Article

The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts

Authors: Young Hee Shin, Jeong Jin Min, Jong-Hwan Lee, Eun-Hee Kim, Go Eun Kim, Myung Hee Kim, Jeong Jin Lee, Hyun Joo Ahn

Published in: Heart and Vessels | Issue 5/2017

Login to get access

Abstract

Independently of the lipid-lowering effects, statin has been reported to attenuate the development of diabetic cardiomyopathy. However, the effect of statin in glucose-controlled diabetic condition has not been demonstrated. We evaluated the effect of fluvastatin on cardiac function, fibrosis, and angiotensin-converting enzyme-2 (ACE2) expression in glucose-controlled diabetic rats. Male Wistar rats were randomly divided into four groups: control (Group C), diabetes (Group D), diabetes with insulin (Group I), and diabetes with insulin and fluvastatin (Group I+F). Diabetes was induced by a single injection of streptozotocin (65 mg/kg). After 8 weeks, the hearts were extracted following echocardiographic evaluation. Cardiac fibrosis was analyzed using Masson’s trichrome stain. Collagens I and III and ACE2 expressions were evaluated by immunohistochemistry and western blot. Group D showed reduced cardiac systolic function compared to the other groups (all P < 0.05). However, diastolic function estimated by E/A ratio was significantly decreased in groups D and I (median: 0.88 and 1.45, respectively) compared to groups C and I+F (2.97 and 2.15) (all P < 0.05). Cardiac fibrosis was more severe in groups D and I than in groups C and I+F (all P < 0.05) on Masson’s trichrome stain. On immunohistochemistry, ACE2 expression was significantly decreased only in group D (all P < 0.05). However, collagen I and III showed higher expressions in group D compared to groups C and I+F while no significant difference was observed compared with group I (all P < 0.05). On western blot, collagen I and ACE2 expressions in group D (median: 1.78 and 0.35, respectively) were significantly different from groups C (references: 1) and I+F (0.76 and 1.21) (all P < 0.05), but not from group I (1.19 and 0.92). Our study suggested a combination of fluvastatin and insulin would be more effective than insulin alone in diabetic hearts. However, the exact mechanism remains to be elucidated.
Literature
1.
go back to reference Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR (1999) Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100:1134–1146CrossRefPubMed Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR (1999) Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100:1134–1146CrossRefPubMed
2.
go back to reference Pappachan JM, Varughese GI, Sriraman R, Arunagirinathan G (2013) Diabetic cardiomyopathy: pathophysiology, diagnostic evaluation and management. World J Diabetes 4:177–189PubMedPubMedCentral Pappachan JM, Varughese GI, Sriraman R, Arunagirinathan G (2013) Diabetic cardiomyopathy: pathophysiology, diagnostic evaluation and management. World J Diabetes 4:177–189PubMedPubMedCentral
3.
go back to reference Falcao-Pires I, Leite-Moreira AF (2012) Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev 17:325–344CrossRefPubMed Falcao-Pires I, Leite-Moreira AF (2012) Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev 17:325–344CrossRefPubMed
4.
go back to reference Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595–602CrossRefPubMed Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595–602CrossRefPubMed
6.
go back to reference Di Bonito P, Cuomo S, Moio N, Sibilio G, Sabatini D, Quattrin S, Capaldo B (1996) Diastolic dysfunction in patients with non-insulin-dependent diabetes mellitus of short duration. Diabet Med 13:321–324CrossRefPubMed Di Bonito P, Cuomo S, Moio N, Sibilio G, Sabatini D, Quattrin S, Capaldo B (1996) Diastolic dysfunction in patients with non-insulin-dependent diabetes mellitus of short duration. Diabet Med 13:321–324CrossRefPubMed
7.
go back to reference Di Bonito P, Moio N, Cavuto L, Covino G, Murena E, Scilla C, Turco S, Capaldo B, Sibilio G (2005) Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging. Diabet Med 22:1720–1725CrossRefPubMed Di Bonito P, Moio N, Cavuto L, Covino G, Murena E, Scilla C, Turco S, Capaldo B, Sibilio G (2005) Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging. Diabet Med 22:1720–1725CrossRefPubMed
8.
go back to reference Nicolino A, Longobardi G, Furgi G, Rossi M, Zoccolillo N, Ferrara N, Rengo F (1995) Left ventricular diastolic filling in diabetes mellitus with and without hypertension. Am J Hypertens 8:382–389CrossRefPubMed Nicolino A, Longobardi G, Furgi G, Rossi M, Zoccolillo N, Ferrara N, Rengo F (1995) Left ventricular diastolic filling in diabetes mellitus with and without hypertension. Am J Hypertens 8:382–389CrossRefPubMed
9.
go back to reference Schannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE (2002) Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 98:33–39CrossRefPubMed Schannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE (2002) Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 98:33–39CrossRefPubMed
10.
go back to reference Dong B, Yu QT, Dai HY, Gao YY, Zhou ZL, Zhang L, Jiang H, Gao F, Li SY, Zhang YH, Bian HJ, Liu CX, Wang N, Xu H, Pan CM, Song HD, Zhang C, Zhang Y (2012) Angiotensin-converting enzyme-2 overexpression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy. J Am Coll Cardiol 59:739–747CrossRefPubMed Dong B, Yu QT, Dai HY, Gao YY, Zhou ZL, Zhang L, Jiang H, Gao F, Li SY, Zhang YH, Bian HJ, Liu CX, Wang N, Xu H, Pan CM, Song HD, Zhang C, Zhang Y (2012) Angiotensin-converting enzyme-2 overexpression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy. J Am Coll Cardiol 59:739–747CrossRefPubMed
11.
go back to reference Singh VP, Baker KM, Kumar R (2008) Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. Am J Physiol Heart Circ Physiol 294:H1675–H1684CrossRefPubMed Singh VP, Baker KM, Kumar R (2008) Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. Am J Physiol Heart Circ Physiol 294:H1675–H1684CrossRefPubMed
12.
go back to reference Imai Y, Kuba K, Ohto-Nakanishi T, Penninger JM (2010) Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ J 74:405–410CrossRefPubMed Imai Y, Kuba K, Ohto-Nakanishi T, Penninger JM (2010) Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ J 74:405–410CrossRefPubMed
13.
go back to reference Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM (2002) Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417:822–828CrossRefPubMed Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM (2002) Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417:822–828CrossRefPubMed
14.
go back to reference Der Sarkissian S, Huentelman MJ, Stewart J, Katovich MJ, Raizada MK (2006) ACE2: a novel therapeutic target for cardiovascular diseases. Prog Biophys Mol Biol 91:163–198CrossRef Der Sarkissian S, Huentelman MJ, Stewart J, Katovich MJ, Raizada MK (2006) ACE2: a novel therapeutic target for cardiovascular diseases. Prog Biophys Mol Biol 91:163–198CrossRef
15.
go back to reference Tikellis C, Pickering R, Tsorotes D, Du XJ, Kiriazis H, Nguyen-Huu TP, Head GA, Cooper ME, Thomas MC (2012) Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes. Clin Sci (Lond) 123:519–529CrossRef Tikellis C, Pickering R, Tsorotes D, Du XJ, Kiriazis H, Nguyen-Huu TP, Head GA, Cooper ME, Thomas MC (2012) Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes. Clin Sci (Lond) 123:519–529CrossRef
16.
go back to reference Bindom SM, Lazartigues E (2009) The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol Cell Endocrinol 302:193–202CrossRefPubMed Bindom SM, Lazartigues E (2009) The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol Cell Endocrinol 302:193–202CrossRefPubMed
17.
go back to reference Liao JK (2005) Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96:24F–33FCrossRefPubMedPubMedCentral Liao JK (2005) Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96:24F–33FCrossRefPubMedPubMedCentral
18.
go back to reference Shida T, Nozawa T, Sobajima M, Ihori H, Matsuki A, Inoue H (2014) Fluvastatin-induced reduction of oxidative stress ameliorates diabetic cardiomyopathy in association with improving coronary microvasculature. Heart Vessels 29:532–541CrossRefPubMed Shida T, Nozawa T, Sobajima M, Ihori H, Matsuki A, Inoue H (2014) Fluvastatin-induced reduction of oxidative stress ameliorates diabetic cardiomyopathy in association with improving coronary microvasculature. Heart Vessels 29:532–541CrossRefPubMed
19.
go back to reference Aguilar C, Ventura F, Rodriguez-Delfin L (2011) Atorvastatin induced increase in homologous angiotensin I converting enzyme (ACE2) mRNA is associated to decreased fibrosis and decreased left ventricular hypertrophy in a rat model of diabetic cardiomyopathy. Rev Peru Med Exp Salud Publica 28:264–272CrossRefPubMed Aguilar C, Ventura F, Rodriguez-Delfin L (2011) Atorvastatin induced increase in homologous angiotensin I converting enzyme (ACE2) mRNA is associated to decreased fibrosis and decreased left ventricular hypertrophy in a rat model of diabetic cardiomyopathy. Rev Peru Med Exp Salud Publica 28:264–272CrossRefPubMed
20.
go back to reference Li YH, Wang QX, Zhou JW, Chu XM, Man YL, Liu P, Ren BB, Sun TR, An Y (2013) Effects of rosuvastatin on expression of angiotensin-converting enzyme 2 after vascular balloon injury in rats. J Geriatr Cardiol 10:151–158PubMedPubMedCentral Li YH, Wang QX, Zhou JW, Chu XM, Man YL, Liu P, Ren BB, Sun TR, An Y (2013) Effects of rosuvastatin on expression of angiotensin-converting enzyme 2 after vascular balloon injury in rats. J Geriatr Cardiol 10:151–158PubMedPubMedCentral
21.
go back to reference Adameova A, Dhalla NS (2014) Role of microangiopathy in diabetic cardiomyopathy. Heart Fail Rev 19:25–33CrossRefPubMed Adameova A, Dhalla NS (2014) Role of microangiopathy in diabetic cardiomyopathy. Heart Fail Rev 19:25–33CrossRefPubMed
22.
go back to reference American Diabetes Association (2015) Cardiovascular disease and risk management. Diabetes Care 38 Suppl:S49–57 American Diabetes Association (2015) Cardiovascular disease and risk management. Diabetes Care 38 Suppl:S49–57
23.
24.
go back to reference Van Linthout S, Riad A, Dhayat N, Spillmann F, Du J, Dhayat S, Westermann D, Hilfiker-Kleiner D, Noutsias M, Laufs U, Schultheiss HP, Tschope C (2007) Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia 50:1977–1986CrossRefPubMed Van Linthout S, Riad A, Dhayat N, Spillmann F, Du J, Dhayat S, Westermann D, Hilfiker-Kleiner D, Noutsias M, Laufs U, Schultheiss HP, Tschope C (2007) Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia 50:1977–1986CrossRefPubMed
25.
go back to reference Chen YH, Feng B, Chen ZW (2012) Statins for primary prevention of cardiovascular and cerebrovascular events in diabetic patients without established cardiovascular diseases: a meta-analysis. Exp Clin Endocrinol Diabetes 120:116–120CrossRefPubMed Chen YH, Feng B, Chen ZW (2012) Statins for primary prevention of cardiovascular and cerebrovascular events in diabetic patients without established cardiovascular diseases: a meta-analysis. Exp Clin Endocrinol Diabetes 120:116–120CrossRefPubMed
26.
go back to reference Bai T, Wang F, Mellen N, Zheng Y, Cai L (2016) Diabetic Cardiomyopathy: role of the E3 Ubiquitin Ligase. Am J Physiol Endocrinol Metab 310(7):E473–E483CrossRefPubMed Bai T, Wang F, Mellen N, Zheng Y, Cai L (2016) Diabetic Cardiomyopathy: role of the E3 Ubiquitin Ligase. Am J Physiol Endocrinol Metab 310(7):E473–E483CrossRefPubMed
27.
go back to reference Cosson S, Kevorkian JP (2003) Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy? Diabetes Metab 29:455–466CrossRefPubMed Cosson S, Kevorkian JP (2003) Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy? Diabetes Metab 29:455–466CrossRefPubMed
28.
go back to reference Nunoda S, Genda A, Sugihara N, Nakayama A, Mizuno S, Takeda R (1985) Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. Heart Vessels 1:43–47CrossRefPubMed Nunoda S, Genda A, Sugihara N, Nakayama A, Mizuno S, Takeda R (1985) Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. Heart Vessels 1:43–47CrossRefPubMed
29.
go back to reference Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR, Haider B (1977) Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 60:884–899CrossRefPubMed Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR, Haider B (1977) Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 60:884–899CrossRefPubMed
30.
go back to reference Fukui M, Goda A, Komamura K, Nakabo A, Masaki M, Yoshida C, Hirotani S, Lee-Kawabata M, Tsujino T, Mano T, Masuyama T (2016) Changes in collagen metabolism account for ventricular functional recovery following beta-blocker therapy in patients with chronic heart failure. Heart Vessels 31:173–182CrossRefPubMed Fukui M, Goda A, Komamura K, Nakabo A, Masaki M, Yoshida C, Hirotani S, Lee-Kawabata M, Tsujino T, Mano T, Masuyama T (2016) Changes in collagen metabolism account for ventricular functional recovery following beta-blocker therapy in patients with chronic heart failure. Heart Vessels 31:173–182CrossRefPubMed
31.
go back to reference Fein FS, Strobeck JE, Malhotra A, Scheuer J, Sonnenblick EH (1981) Reversibility of diabetic cardiomyopathy with insulin in rats. Circ Res 49:1251–1261CrossRefPubMed Fein FS, Strobeck JE, Malhotra A, Scheuer J, Sonnenblick EH (1981) Reversibility of diabetic cardiomyopathy with insulin in rats. Circ Res 49:1251–1261CrossRefPubMed
32.
go back to reference Dai QM, Lu J, Liu NF (2011) Fluvastatin attenuates myocardial interstitial fibrosis and cardiac dysfunction in diabetic rats by inhibiting over-expression of connective tissue growth factor. Chin Med J (Engl) 124:89–94 Dai QM, Lu J, Liu NF (2011) Fluvastatin attenuates myocardial interstitial fibrosis and cardiac dysfunction in diabetic rats by inhibiting over-expression of connective tissue growth factor. Chin Med J (Engl) 124:89–94
33.
go back to reference Ihori H, Nozawa T, Sobajima M, Shida T, Fukui Y, Fujii N, Inoue H (2016) Waon therapy attenuates cardiac hypertrophy and promotes myocardial capillary growth in hypertensive rats: a comparative study with fluvastatin. Heart Vessels 31:1361–1369CrossRefPubMed Ihori H, Nozawa T, Sobajima M, Shida T, Fukui Y, Fujii N, Inoue H (2016) Waon therapy attenuates cardiac hypertrophy and promotes myocardial capillary growth in hypertensive rats: a comparative study with fluvastatin. Heart Vessels 31:1361–1369CrossRefPubMed
34.
go back to reference Nishimura RA, Tajik AJ (1997) Evaluation of diastolic filling of left ventricle in health and disease: doppler echocardiography is the clinician’s Rosetta Stone. J Am Coll Cardiol 30:8–18CrossRefPubMed Nishimura RA, Tajik AJ (1997) Evaluation of diastolic filling of left ventricle in health and disease: doppler echocardiography is the clinician’s Rosetta Stone. J Am Coll Cardiol 30:8–18CrossRefPubMed
35.
go back to reference Hurrell DG, Nishimura RA, Ilstrup DM, Appleton CP (1997) Utility of preload alteration in assessment of left ventricular filling pressure by Doppler echocardiography: a simultaneous catheterization and Doppler echocardiographic study. J Am Coll Cardiol 30:459–467CrossRefPubMed Hurrell DG, Nishimura RA, Ilstrup DM, Appleton CP (1997) Utility of preload alteration in assessment of left ventricular filling pressure by Doppler echocardiography: a simultaneous catheterization and Doppler echocardiographic study. J Am Coll Cardiol 30:459–467CrossRefPubMed
36.
go back to reference Ikeda Y, Inomata T, Fujita T, Iida Y, Kaida T, Nabeta T, Ishii S, Maekawa E, Yanagisawa T, Mizutani T, Naruke T, Koitabashi T, Takeuchi I, Ako J (2016) Higher hemoglobin A1c levels are associated with impaired left ventricular diastolic function and higher incidence of adverse cardiac events in patients with nonischemic dilated cardiomyopathy. Heart Vessels. doi:10.1007/s00380-016-0895-x PubMedCentral Ikeda Y, Inomata T, Fujita T, Iida Y, Kaida T, Nabeta T, Ishii S, Maekawa E, Yanagisawa T, Mizutani T, Naruke T, Koitabashi T, Takeuchi I, Ako J (2016) Higher hemoglobin A1c levels are associated with impaired left ventricular diastolic function and higher incidence of adverse cardiac events in patients with nonischemic dilated cardiomyopathy. Heart Vessels. doi:10.​1007/​s00380-016-0895-x PubMedCentral
37.
go back to reference Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, Ohmori K, Matsuo H (2000) Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 101:899–907CrossRefPubMed Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, Ohmori K, Matsuo H (2000) Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 101:899–907CrossRefPubMed
38.
go back to reference Ferreira AJ, Shenoy V, Qi Y, Fraga-Silva RA, Santos RA, Katovich MJ, Raizada MK (2011) Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 96:287–294CrossRefPubMed Ferreira AJ, Shenoy V, Qi Y, Fraga-Silva RA, Santos RA, Katovich MJ, Raizada MK (2011) Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 96:287–294CrossRefPubMed
39.
go back to reference Simoes e Silva AC, Silveira KD, Ferreira AJ, Teixeira MM (2013) ACE2, angiotensin-(1–7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol 169:477–492CrossRefPubMedPubMedCentral Simoes e Silva AC, Silveira KD, Ferreira AJ, Teixeira MM (2013) ACE2, angiotensin-(1–7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol 169:477–492CrossRefPubMedPubMedCentral
40.
go back to reference Bambace C, Sepe A, Zoico E, Telesca M, Olioso D, Venturi S, Rossi A, Corzato F, Faccioli S, Cominacini L, Santini F, Zamboni M (2014) Inflammatory profile in subcutaneous and epicardial adipose tissue in men with and without diabetes. Heart Vessels 29:42–48CrossRefPubMed Bambace C, Sepe A, Zoico E, Telesca M, Olioso D, Venturi S, Rossi A, Corzato F, Faccioli S, Cominacini L, Santini F, Zamboni M (2014) Inflammatory profile in subcutaneous and epicardial adipose tissue in men with and without diabetes. Heart Vessels 29:42–48CrossRefPubMed
41.
go back to reference Erdos B, Snipes JA, Tulbert CD, Katakam P, Miller AW, Busija DW (2006) Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production. Am J Physiol Heart Circ Physiol 290:H1264–H1270CrossRefPubMed Erdos B, Snipes JA, Tulbert CD, Katakam P, Miller AW, Busija DW (2006) Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production. Am J Physiol Heart Circ Physiol 290:H1264–H1270CrossRefPubMed
42.
go back to reference Hsueh W, Abel ED, Breslow JL, Maeda N, Davis RC, Fisher EA, Dansky H, McClain DA, McIndoe R, Wassef MK, Rabadan-Diehl C, Goldberg IJ (2007) Recipes for creating animal models of diabetic cardiovascular disease. Circ Res 100:1415–1427CrossRefPubMed Hsueh W, Abel ED, Breslow JL, Maeda N, Davis RC, Fisher EA, Dansky H, McClain DA, McIndoe R, Wassef MK, Rabadan-Diehl C, Goldberg IJ (2007) Recipes for creating animal models of diabetic cardiovascular disease. Circ Res 100:1415–1427CrossRefPubMed
Metadata
Title
The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts
Authors
Young Hee Shin
Jeong Jin Min
Jong-Hwan Lee
Eun-Hee Kim
Go Eun Kim
Myung Hee Kim
Jeong Jin Lee
Hyun Joo Ahn
Publication date
01-05-2017
Publisher
Springer Japan
Published in
Heart and Vessels / Issue 5/2017
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-016-0936-5

Other articles of this Issue 5/2017

Heart and Vessels 5/2017 Go to the issue